The use of cyproheptadine (a 5-HT2 receptor blocker) has been the long-time anecdotal treatment most discussed when treating SS but has been found to be of limited clinical use since most hospitals in the US may only carry the oral form. The gene discussed is HTR2A; the disease is synovial sarcoma.